SGLT-2 inhibitors and GLP-1 analogues are in the right place as second line therapies in type 2 diabetes, a study presented at conference has concluded. The research presented by endocrinologist Dr David Hoffman from the Australian Diabetes Informatics Group (DINGO) set out to test the efficacy and durability of SGLT-2 inhibitors with GLP-1 analogues in ...
Type 2 diabetes
New type 2 players in their right treatment place
By Nicola Garrett
31 Aug 2017